Madrigal Pharmaceuticals (MDGL) Total Non-Current Liabilities (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has reported Total Non-Current Liabilities for 14 consecutive years, with $346.7 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Total Non-Current Liabilities rose 182.11% year-over-year to $346.7 million; the TTM figure through Jun 2026 stood at $346.7 million (up 182.11% YoY), while the FY2025 annual figure was $346.6 million, up 192.28% from the prior year.
• Total Non-Current Liabilities was little changed at $346.7 million in Q2 2026 per MDGL's latest filing, from $345.6 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $346.7 million in Q2 2026 and bottomed at $283000.0 in Q1 2022.
• Historically, Total Non-Current Liabilities has averaged $147.8 million across 5 years, with a median of $117.3 million in 2024.
• Annual changes were most pronounced in 2022 — Total Non-Current Liabilities fell 26.87% — and 2023, when it soared 29569.61%.
• Madrigal Pharmaceuticals' Total Non-Current Liabilities stood at $49.3 million in 2022, then surged by 136.7% to $116.7 million in 2023, then increased by 1.65% to $118.6 million in 2024, then jumped by 192.28% to $346.6 million in 2025, then increased by 0.03% to $346.7 million in 2026.
• Business Quant data shows MDGL's Total Non-Current Liabilities at $346.7 million in Q2 2026, $345.6 million in Q1 2026, and $346.6 million in Q4 2025.